Two medical journals publish retractions on two papers related to atorvastatin, brain bleeding

Tim Casey | | Cardiovascular Business | Patient Care

Two medical journals recently retracted a pair of papers about the possible use of atorvastatin to treat bleeding on the brain, Retraction Watch reports.

The website noted that the papers were published last year in the Journal of Neurosurgery and Frontiers in Neuroscience. The papers shared the following authors: Hua Liu, Zhongkun Liu, Jian Yang and Shifeng Kan.

Atorvastatin is used to treat high cholesterol and is the generic name for Lipitor, the blockbuster drug that lost patent protection in 2011.

Read the full article below:

Authors retract two statin papers, one with problems “too extensive to revise”

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Related Content

ASNC and AMA push back against AI prior authorization denials
FDA declares Class I recall on heart surgery procedure kits from Medline
AMA president warns prior authorization hurting patients, driving burnout and practice closures
Cardiology societies should develop separate guidelines for treating female heart patients
Inflammation playing a much bigger role in heart disease evaluations
Heart patients benefit when cardiologists follow a standardized TAVR protocol

Around the web

Health Exec
Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging
Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business
U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.